Coronary Artery Disease
Conditions
Keywords
DES, CAD, EXCEL-II, JWMS, PCI
Brief summary
The study aims to further assess the safety, efficacy and the performance of its delivery system of the new generation Sirolimus-eluting stent of JWMS up to five years.
Detailed description
1. A prospective, a single set, multicenter clinical trial; 2. The primary in situ in patients with coronary heart disease; 3. The center of: 28 (the actual number of center shall prevail);The plan selected 621 patients;(where the total number of cases in 2.25 mm specification not less than 30 cases, 5 cases each specification of not less than 2.25 mm.) 4. Clinical follow-up time points: 1 months, 6 months, 12 months and 18 months of a year and 2 years to 5 years follow-up; This test by an independent coronary angiography core laboratories, data management and statistical center, clinical end points to judge committee and clinical monitoring of all relevant clinical and imaging data collecting, sorting, statistical analysis and judgement.All the selected patients within five years continuous follow-up tracking (phone or outpatient follow-up), to observe the happening of adverse events to the forward of the second generation of EXCEL drug-eluting stents (des) system security to make more accurate and credible evaluation.
Interventions
DEVICEEXCEL-II biodegradable polymer sirolimus-eluting stent
EXCEL-II biodegradable polymer sirolimus-eluting stent implantation
Sponsors
JW Medical Systems Ltd
Study design
Observational model
CASE_ONLY
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1.18yrs≤Age≤75yrs . 2..stability and unstable angina pectoris (AP), chronic myocardial infarction (OMI) or confirmed (myocardial ischemia; 3.De novo lesion at native coronary artery(Up to four target lesions). 4.Lesion length ≤60mm. 5.RVD 2.25mm～4.0mm. 6.DS%≥70% by visual estimation. 7.Coronary artery bypass surgery (coronary artery bypass grafting) patients. 8.Subjects are willing to follow the specified requirements follow-up. 9.To understand the purpose of testing, voluntary and signed informed consent, willing to accept the imaging and clinical follow-up of subjects.
Exclusion criteria
1. AMI within 7 days. 2. Left main lesion, transplant vasculopathy and stent restenosis lesion; 3. Severe calcified lesion unable to predilate. 4. The distortion of the stent was hampered by lesions. 5. NYHA≥Ⅲ or LVEF\<35%. 6. Prior PCI within 1 year. 7. Pregnancy or lactation, and planning pregnancy or lactation. 8. Subjects have bleeding tendency or blood coagulation dysfunction or PCI contraindications, or anticoagulant therapy taboo or can't continue to take DAPT at least 1 year. 9. There are other diseases (such as cancer,malignant tumor ,congestive heart failure,organ transplantation or candidate) or abuse history (alcohol cocaine heroin, etc.), scheme compliance is poor, interference related data explanation or the limited life (\< 1 year). 10. To aspirin heparin clopidogrel cobalt chromium alloy rapamycin PLA polymer contrast agent of one of allergy. 11. Serious liver and kidney function are not complete subject(ALT and AST were three times greater than the upper limit of normal). 12. Before enrolling to participate in other clinical trials and not reached the primary endpoint. 13. Non-compliant subject and could not finish the trial in accordance with the requirements of the subjects.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The Target Lesion Failure(TLF) as the primary endpoint at 12-month | 12months | Device-related cardiovascular composite endpoint, including cardiac death, target vessel MI and clinically driven TLR at 12 months post procedure |
Secondary
| Measure | Time frame |
|---|---|
| Stent implantation success rate | 5 Years |
| TLF, cardiovascular composite endpoints, ARC defined stent thrombosis | 30 days, 6 months, and 2-5 years |
Countries
China
Outcome results
None listed